Subsequent Events

3 Months Ended

Mar. 31, 2020

Subsequent Events

Subsequent Events

14.          Subsequent Events

The Company has evaluated subsequent events that may require adjustments to or disclosure in the unaudited interim condensed consolidated financial statements through May 12, 2020, the date on which the unaudited interim condensed consolidated financial statements were available to be issued.

In April, the Company announced plans to collaborate with BeiGene Ltd. (Beigene) and IGM Biosciences, Inc. (IGM), which enable the parties to leverage their combined technology and expertise to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The Company and IGM executed a Material Transfer and Collaboration Agreement (the MTCA) to allow both parties to commence their respective efforts and all three parties expect to work to finalize the financial and operational details of the collaboration in the coming months.